Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms.
Due to the intrinsic resistance of Burkholderia cepacia complex (Bcc) to many antibiotics and the production of a broad range of virulence factors, lung infections by these bacteria, primarily occurring in cystic fibrosis (CF) patients, are very difficult to treat. In addition, the ability of Bcc organisms to form biofilms contributes to their persistence in the CF lung. As Bcc infections are associated with poor clinical outcome, there is an urgent need for new effective therapies to treat these infections. In the present study, we investigated whether liposomal tobramycin displayed an increased anti-biofilm effect against Bcc bacteria compared to free tobramycin. Single particle tracking (SPT) was used to study the transport of positively and negatively charged nanospheres in Bcc biofilms as a model for the transport of liposomes. Negatively charged nanospheres became immobilized in close proximity of biofilm cell clusters, while positively charged nanospheres interacted with fiber-like structures, probably eDNA. Based on these data, encapsulation of tobramycin in negatively charged liposomes appeared promising for targeted drug delivery. However, the anti-biofilm effect of tobramycin encapsulated into neutral or anionic liposomes did not increase compared to that of free tobramycin. Probably, the fusion of the anionic liposomes with the negatively charged bacterial surface of Bcc bacteria was limited by electrostatic repulsive forces. The lack of a substantial anti-biofilm effect of tobramycin encapsulated in neutral liposomes could be further investigated by increasing the liposomal tobramycin concentration. However, this was hampered by the low encapsulation efficiency of tobramycin in these liposomes.
Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
Anne-Sophie
AS
Messiaen
Katrien
K
Forier
Hans
H
Nelis
Kevin
K
Braeckmans
Tom
T
Coenye
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects*; D001692:Biological Transport / Q000187:drug effects; D016956:Burkholderia cepacia / Q000502:physiology*; D016503:Drug Delivery Systems; D008081:Liposomes / Q000493:pharmacokinetics / Q000494:pharmacology; D053758:Nanoparticles; D014031:Tobramycin / Q000493:pharmacokinetics / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D008081:Liposomes; D014031:Tobramycin